11/14
10:01 am
cgem
Cullinan Therapeutics Announces Preclinical Data for CLN-978, a CD19-directed T Cell Engager, to be Presented at ACR Convergence 2024
Low
Report
Cullinan Therapeutics Announces Preclinical Data for CLN-978, a CD19-directed T Cell Engager, to be Presented at ACR Convergence 2024
11/7
07:00 am
cgem
Cullinan Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results
Medium
Report
Cullinan Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results
11/5
07:00 am
cgem
Cullinan Therapeutics to Participate in Fireside Chat at Stifel 2024 Healthcare Conference
Low
Report
Cullinan Therapeutics to Participate in Fireside Chat at Stifel 2024 Healthcare Conference
11/4
07:00 am
cgem
Cullinan Therapeutics to Present Preclinical Data for CLN-978, a CD19-directed T Cell Engager, at ACR Convergence 2024
Low
Report
Cullinan Therapeutics to Present Preclinical Data for CLN-978, a CD19-directed T Cell Engager, at ACR Convergence 2024
10/24
07:16 am
cgem
Cullinan Therapeutics, Inc. (NASDAQ: CGEM) is now covered by analysts at UBS Group AG. They set a "buy" rating and a $30.00 price target on the stock.
Low
Report
Cullinan Therapeutics, Inc. (NASDAQ: CGEM) is now covered by analysts at UBS Group AG. They set a "buy" rating and a $30.00 price target on the stock.
10/16
03:44 pm
cgem
Cullinan Therapeutics, Inc. (NASDAQ: CGEM) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $28.00 price target on the stock.
Low
Report
Cullinan Therapeutics, Inc. (NASDAQ: CGEM) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $28.00 price target on the stock.
10/16
07:00 am
cgem
Cullinan Therapeutics Receives U.S. FDA Clearance of Investigational New Drug Application for CLN-978 Administered Subcutaneously in Patients with Moderate to Severe Systemic Lupus Erythematosus
Medium
Report
Cullinan Therapeutics Receives U.S. FDA Clearance of Investigational New Drug Application for CLN-978 Administered Subcutaneously in Patients with Moderate to Severe Systemic Lupus Erythematosus
9/18
09:15 am
cgem
Cullinan Therapeutics, Inc. (NASDAQ: CGEM) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $36.00 price target on the stock.
Low
Report
Cullinan Therapeutics, Inc. (NASDAQ: CGEM) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $36.00 price target on the stock.
9/17
07:00 am
cgem
Cullinan Therapeutics Receives Approval to Initiate its Global Phase 1 Clinical Trial of CLN-978 for the Treatment of Systemic Lupus Erythematosus
Low
Report
Cullinan Therapeutics Receives Approval to Initiate its Global Phase 1 Clinical Trial of CLN-978 for the Treatment of Systemic Lupus Erythematosus
9/16
08:03 am
cgem
Cullinan Therapeutics, Inc. (NASDAQ: CGEM) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $28.00 price target on the stock.
High
Report
Cullinan Therapeutics, Inc. (NASDAQ: CGEM) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $28.00 price target on the stock.
9/16
07:00 am
cgem
Cullinan Therapeutics Announces Submission of Investigational New Drug Application to U.S. Food and Drug Administration for CLN-978 to Treat Systemic Lupus Erythematosus
High
Report
Cullinan Therapeutics Announces Submission of Investigational New Drug Application to U.S. Food and Drug Administration for CLN-978 to Treat Systemic Lupus Erythematosus
9/14
04:15 am
cgem
Cullinan Therapeutics Presents Positive Updated Data from Module C of Zipalertinib Pivotal Phase 2b Study at ESMO 2024
High
Report
Cullinan Therapeutics Presents Positive Updated Data from Module C of Zipalertinib Pivotal Phase 2b Study at ESMO 2024
8/30
01:38 pm
cgem
Cullinan Therapeutics: Fundraising Capability, Emergence In Autoimmune Disease [Seeking Alpha]
Low
Report
Cullinan Therapeutics: Fundraising Capability, Emergence In Autoimmune Disease [Seeking Alpha]
8/28
08:00 am
cgem
Cullinan Therapeutics to Participate in Upcoming Investor Conferences
Low
Report
Cullinan Therapeutics to Participate in Upcoming Investor Conferences